2018, Número 1
<< Anterior
Vet Mex 2018; 5 (1)
Establishment and maintenance of an R6/1 transgenic mouse colony and validation of its progressive neurological phenotype to study Huntington’s disease
García-Lara L, Morales-Martínez A, Angeles-López QD, Pedraza-Espitia H, Pérez-Neri I, Rodríguez-Balderas CA, Pérez-Severiano F
Idioma: Español/Inglés
Referencias bibliográficas: 17
Paginas: 1-12
Archivo PDF: 701.21 Kb.
RESUMEN
Sin resumen.
REFERENCIAS (EN ESTE ARTÍCULO)
Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord. 2012;27:1083-91. doi: 10.1002/mds.25075.
Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE, et al. A polymorphic DNA marker genetically linked to Huntington’s disease. Nat Genet. 1983;306:234-8. doi: 10.1038/306234a0.
MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Srinidhi CLL, Barnes G, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72:971-83. doi: /10.1016/0092-8674(93)90585-E.
Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nat Genet. 1993;4:398-403. doi: /10.1038/ ng0893-398.
Estrada Sánchez AM, Mejia-Toiber J, Massieu L. Excitotoxic neuronal death and the pathogenesis of Huntington’s disease. Arch Med Res. 2008;39:265-76. doi: 10.1016/j.arcmed.2007.11.011.
von Hörsten S, Schmitt I, Nguyen HP, Holzmann C, Schmidt T, Walther T, et al. Transgenic rat model of Huntington’s disease. Human molecular genetics. Hum Mol Genet. 2003;12:617-24. doi: 10.1093/hmg/ddg075.
Uchida M, Shimatsu Y, Onoe K, Matsuyama N, Niki R, Ikeda JE, et al. Production of transgenic miniature pigs by pronuclear microinjection. Transgenic Res. 2001;10:577-82.
Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng EC, et al. Towards a transgenic model of Huntington’s disease in a non-human primate. Nature. 2008;453(7197):921-4. doi: 10.1038/nature06975.
Jacobsen JC, Bawden CS, Rudiger SR, McLaughlan CJ, Reid SJ, Waldvogel HJ, et al. An ovine transgenic Huntington’s disease model. Hum Mol Genet. 2010;19:1873-82. doi: 10.1093/hmg/ddq063.
Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996;87:493-506. doi: 10.1016/S0092-8674(00)81369-0.
Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington’s disease. Nat Rev Neurosci. 2004;5:373-84. doi: /10.1038/ nrn1386.
Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington’s disease. Nat Rev Neurosci. 2013;14. doi: 10.1038/nrn3570.
Ferrante RJ. Mouse models of Huntington’s disease and methodological considerations for therapeutic trials. Biochim Biophys Acta. 2009;1792:506-20. doi: 10.1016/j.bbadis.2009.04.001.
Chang R, Liu X, Li S, Li XJ. Transgenic animal models for study of the pathogenesis of Huntington’s disease and therapy. Drug Des Devel Ther. 2015;9:2179- 88. doi: /10.2147/DDDT.S58470.
Zheng Z, Diamond MI. Huntington disease and the huntingtin protein. Prog Mol Biol Transl Sci. 2012;107:189-214. doi: 10.1016/B978-0-12-385883-2.00010-2.
Andreassen OA, Dedeoglu A, Stanojevic V, Hughes DB, Browne SE, Leech CA, et al. Huntington’s disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol Dis. 2002;11:410-24. doi: /10.1006/nbdi.2002.0562.
Perez-Severiano F, Rios C, Segovia J. Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington’s disease. Brain research. 2000;862(1-2):234-7. doi: 10.1016/ S0006-8993(00)02082-5.
Texto completo
Cómo citar este artículo